AgingResearch.NewsJoin free

Amplio Pharma

CompanyDenmark

Amplio Pharma develops one asset, in phase 1 (NovoBioJect in rheumatoid arthritis). Mostly device acting on inflammation; based in Denmark.

1
Asset
Furthest stage
Phase 1
0
Trials
0
Signals

Pipeline

1

  • NovoBioJect

    Enhances cellular uptake/activation of methotrexate in immune cells.

    Phase 1, Device, Inflammation, rheumatoid arthritis

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Evidence behind the mechanisms1
  • Similar companies6

Intelligence